Retirement Systems of Alabama Increases Stake in C.R. Bard, Inc. (NYSE:BCR)
Retirement Systems of Alabama boosted its position in C.R. Bard, Inc. (NYSE:BCR) by 0.8% during the second quarter, Holdings Channel reports. The institutional investor owned 35,112 shares of the medical instruments supplier’s stock after buying an additional 295 shares during the period. Retirement Systems of Alabama’s holdings in C.R. Bard were worth $11,099,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Cribstone Capital Management LLC purchased a new stake in C.R. Bard during the first quarter worth approximately $130,000. Whittier Trust Co. increased its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares in the last quarter. ClariVest Asset Management LLC purchased a new stake in C.R. Bard during the first quarter worth approximately $148,000. SRS Capital Advisors Inc. increased its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares in the last quarter. 85.32% of the stock is currently owned by institutional investors.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 319.13 on Friday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The firm has a market capitalization of $23.19 billion, a price-to-earnings ratio of 41.90 and a beta of 0.59. The stock’s 50 day moving average price is $318.89 and its 200-day moving average price is $282.81.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same period last year, the company earned $2.54 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. On average, equities research analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were given a $0.26 dividend. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.67%.
A number of analysts have recently commented on BCR shares. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research note on Tuesday, June 13th. BidaskClub downgraded C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Morgan Stanley downgraded C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Jefferies Group LLC boosted their price objective on C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research note on Monday, April 24th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $285.67.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.